AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02787109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTH522-CAF01
Description: CTH522 chlamydia antigen adjuvanted with CAF01 for IM administration
Study NCT02787109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTH522-Al(OH)3
Description: CTH522 chlamydia antigen adjuvanted with aluminium hydroxide, Al(OH)3 , for IM administration
Study NCT02787109 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT03518112 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV
Study NCT03518112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03518112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV
Study NCT03518112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: PO or IV
Study NCT03518112 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT03518112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03518112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT03518112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO
Study NCT03518112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT or IV
Study NCT02839993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training
Study NCT02839993 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: training
Study NCT02718287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visiting intervention PCCSF (220 clusters)
Description: Low income mothers of children 0-2.5 years of age in the randomized treatment micro-areas will receive home visits by community health workers trained in the PCCSF curriculum in addition to the basic health curriculum. The community health workers are supervised by trained and experienced nurses.
Study NCT02718287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visiting without PCCSF (220 clusters)
Description: Low income mothers of children 0-2.5 years of age in the randomized control micro-areas will receive home visits by community health workers trained in the standard basic health curriculum (no PCCSF).
Study NCT03518112 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC
Study NCT03518112 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT03518112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT02674633 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AKL-T01
Description: Videogame-like digital therapy
Study NCT02674633 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AKL-T09
Description: Videogame-like digital therapy
Study NCT00493064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinic acid
Description: topical eye drops
Study NCT00493064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate
Description: topical eye drops
Study NCT01684215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: PD-0332991 (100 mg or 125 mg) will be orally administered once a day for 3 weeks followed by 1 week off treatment, in the morning on an empty stomach. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
Study NCT01684215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
Study NCT01684215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
Study NCT02784340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivicaine and Fentany
Study NCT00778739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL
Study NCT00778739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL
Study NCT01546155 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET imaging
Description: Up to a 120 minute PET scan using \[11C\]diprenorphine as the radiotracer
Study NCT01544140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral syrup 7.5 mg, single dose
Study NCT01544140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Description: Oral tablets, 800 mg, single dose
Study NCT02824939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane (TAP) Block
Description: 0.5 ml/kg of 0.25 % Bupivacaine deposited in the transversus abdominis plane under ultrasound guidance postoperatively
Study NCT02824939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum (QL) Block
Description: 0.5 ml/kg of 0.25 % Bupivacaine deposited in the anterolateral aspect of the quadratus lumborum muscle under ultrasound guidance postoperatively
Study NCT03392558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Burt's Bees Skin Care Regimen
Description: Burt's Bees Facial Cleanser (twice daily), Burt's Bees Sensitive Daily Moisturizing Cream (morning), Burt's Bees Sensitive Night Cream (at bedtime)
Study NCT03392558 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Regimen
Description: Cetaphil Gentle Skin Cleanser (twice daily), Cetaphil Moisturizing Lotion (twice daily)
Study NCT00954707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel & Aspirin, Prasugrel & Aspirin
Description: This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of thienopyridine treatment in addition to aspirin.
Study NCT00954707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo & Aspirin
Description: This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
Study NCT04630457 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ankle prosthesis
Description: At the first visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using the conventional prosthesis that the patient had.
Study NCT04630457 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Meridium® (Microprocessor ankle prosthesis)
Description: There are two weeks apart between each visit. Depending on the group to which the patient belongs, at the second or third visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using Meridium®. For example, if visit 2 was evaluated using Meridium®, visit 3 was evaluated using RoFT®. In another example, visit 2 is evaluated using RoFT®, while Visit 3 is evaluated using Meridium®.
Study NCT00977431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: During RT: 75 mg/m2 daily , 4 weeks after RT: given days 1 to 5 of 28 day cycles (150 mg/m2 in cycle 1, 200 mg/m2 in cycle 2 up to cycle 6)
Study NCT00977431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Day 1 to day 42
Study NCT02784340 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 25G spinal needles
Study NCT00977431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW2992
Description: Escalating dose cohorts during Radiotherapy(RT) period, fixed dose after RT
Study NCT02784340 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 25G spinal needles
Study NCT03410160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical and biochemical examination.
Description: Patients with chronic adrenal insufficiency were assessed by clinical and biochemical examination as well as questionnaire to evaluate the quality of hormone replacement therapy with glucocorticoids, education status, cortisol-metabolism, catecholamine deficit, chronic inflammation and variations of the glucocorticoid receptor.
Study NCT03586973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib tablet
Study NCT00977431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW2992
Description: Escalating dose cohorts during Radiotherapy(RT) period , fixed dose after RT
Study NCT00338130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: Oral liquid or Capsule
Study NCT00338130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: oral
Study NCT02487082 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Melatonin and Donepezil
Description: 10 weeks of active study medication in Group A during Phase 1 \& Phase 2. 5 weeks of active study medication in Group B during Phase 2.
Study NCT02487082 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: For both groups: 5 weeks of Placebo in the Run-In Phase. For Group B: an addition 5 weeks of Placebo in Phase 1.
Study NCT00813826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLC022
Description: SLC022 150 mg capsule, 900mg daily dose
Study NCT00813826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, TID
Study NCT00813826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule, TID
Study NCT03451006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral metformin (up to 2gm) will be given in divided doses
Study NCT03451006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Placebo will be given in divided doses
Study NCT02117388 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Restriction
Description: Sleep Restriction therapy will limit the time spent in bed in order to make sure participants are sleepy enough to fall asleep quickly.
Study NCT02117388 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep.
Study NCT02117388 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Therapy
Description: Sleep Restriction and Cognitive Therapy will be combined so that the two therapies reinforce each other.
Study NCT03708016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot gait training
Description: Lokomat robot training was applied to stroke patients.
Study NCT03708016 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robot gait training
Description: Lokomat robot training was applied to stroke patients.
Study NCT00908219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is given as an IV infusion of 15 mg/kg every three weeks for 12 weeks.
Study NCT03015064 — intervention group
Intervention type: OTHER
Intervention: Myocardial Infarction
Description: Observational study of myocardial Infarction patients
Study NCT01337765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235 + MEK162
Study NCT03708016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain stimulation
Description: tDCS brain stimulation on leg motor areas was applied to stroke patients.
Study NCT04654234 — intervention group
Intervention type: DEVICE
Intervention: Total body PET/CT (uExplorer)
Description: A total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER) with a 192-cm scan range was applied for cancer diagnosis, organ function assessment and treatment outcome prediction. The total-body PET scanner can acquire scans with lower administered activity or short acquisition time, total-body dynamic acquisition at a longer delayed time point, and high detectability of exiguous changes of the whole body, and tumor as well.
Study NCT03902899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention (oral presentation)
Description: A brief oral presentation (30-45 minutes) which focused on making endoscopists aware of the significance and characteristics of serrated polyps.
Study NCT00003130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00855075 — intervention group
Intervention type: DEVICE
Intervention: Cerebral State Monitor
Description: A cerebral state monitor will provide a cerebral state index for mechanically ventilated intensive care patients. Recorded cerebral state indexes will be correlated with clinical assessments of sedation using the Richmond Agitation-Sedation Scale.
Study NCT02137694 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: vaginal auto-takings and urinary test
Description: vaginal auto-takings and urinary test
Study NCT02343354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition/physical activity intervention
Description: Please see arm description
Study NCT00503230 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Intervention (SCI)
Description: Standard Care Intervention (SCI)
Study NCT00503230 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Culturally Tailored Intervention (CTI)
Description: Culturally Tailored Intervention (CTI)
Study NCT01470417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with low risk disease will have an additional two cycles of therapy (4 total cycles) prior to resection.
Study NCT01470417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy + ChemoRadiotherapy
Description: Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with high-risk or borderline resectable disease will receive additional chemotherapy with radiation therapy prior to resection.
Study NCT04628845 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endo-perio therapy with laser 940nm
Description: Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals with using laser 940nm.
Study NCT04628845 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Endo-perio therapy without laser 940nm
Description: Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals
Study NCT00730951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng
Description: 500mg Capsulated Ground Dried Korean Red Ginseng Root
Study NCT03964532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib (formerly MDV3800 and BMN673) is an oral small molecule, selective inhibitor of PARP-1 and PARP-2.
Study NCT03964532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab (formerly MSB0010718C) is a human immunoglobulin G1 (IgG1) anti-PD-L1 monoclonal antibody131 that utilizes both adaptive and innate immune mechanisms.
Study NCT00942981 — intervention group
Intervention type: DRUG
Intervention: PET
Description: Brain dopamine D1 and D2/3 receptor regional binding potentials measured by \[11C\]NNC-112 and \[18F\]Fallypride PET.
Study NCT03049462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Women will take 100mg daily for 4 weeks. Men will take 200mg daily for 4 weeks. The medication is available in 50 mg tablets.
Study NCT03049462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: Women will take 100mg daily for 4 weeks. Men will take 200mg daily for 4 weeks. The medication is available in 50 mg tablets.
Study NCT03049462 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: B Complex Plus Vitamin C Tablets
Description: Males will be randomized to take placebo versus active drug (mirabegron). Those taking placebo will take 4 tablets each day to mirror to active group (taking 4 tablets of 50 mg each).
Study NCT01626742 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ready to Drink Flavored Beverage
Description: 2 servings a day
Study NCT01626742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ready to drink flavored beverage w/ AN 777
Description: 2 servings a day
Study NCT01689948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home rehabilitation therapy
Description: 12 sessions of home rehabilitation therapy
Study NCT03237702 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-Carotenoids
Description: All participants in the second stage will receive multi-carotenoids 30 mg qd for 8 weeks.
Study NCT02965716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02965716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Given IL
Study NCT04630457 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RoFT® (Microprocessor ankle prosthesis)
Description: There are two weeks apart between each visit. Depending on the group to which the patient belongs, at the second or third visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using RoFT®. For example, if visit 2 was evaluated using RoFT®, visit 3 was evaluated using Meridium®. In another example, visit 2 is evaluated using Meridium®, while Visit 3 is evaluated using RoFT®.
Study NCT04182087 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive tasks
Description: Attention, language, memory, decision-making or executive functions
Study NCT02305082 — intervention group
Intervention type: OTHER
Intervention: Fast-track group
Description: Enhanced recovery after surgery pathway. Postoperatively, a set of well-defined discharge criteria will be assessed daily at 9:00 and 15:00, as well as pain, nausea, time to flatus, saturation and drain production.
Study NCT01801930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCV-103 and OCV-104
Description: 0.3 mg of each
Study NCT01801930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCV-103 and OCV-104
Description: 1 mg of each
Study NCT01801930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCV-103 and OCV-104
Description: 3 mg of each
Study NCT01801930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCV-103 and OCV-104
Description: 6 mg of each
Study NCT03841019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magpro X100 + Option
Description: In addition to treatment as usual (TAU), participants were supposed to receive twelve sessions of MST in four weeks (three sessions per week)
Study NCT03841019 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ThymatronSystem Ⅳ Electroconvulsive System
Description: In addition to treatment as usual (TAU), participants were supposed to receive twelve sessions of ECT in four weeks (three sessions per week)
Study NCT03702400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine 100 mcg
Description: Phenylephrine at a dose of 100 mcg bolus at a dilution containing 20 mcg / mL of the drug, 5 mL each bolus
Study NCT03702400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine 5 mcg
Description: Norepinephrine at a dose of 5 mcg at dilution containing 1 mcg / mL, 5 mL each bolus
Study NCT03200587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10 mg/kg infusion every 2 weeks (Days 1 and 15) of every 28 day cycle for up to 12 cycles